Prevalence, characterization and antibiotic resistance of Pasteurella multocida isolated from bovine respiratory infection

Jamali, Hossein; Rezagholipour, Mojtaba; Fallah, Sepideh; Dadrasnia, Arezoo; Chelliah, Shamini; Velappan, Rita Devi; Wei, Kelvin Swee Chuan; Ismail, Salmah

doi:10.1016/j.tvjl.2014.07.024

Cited by 25 publications

(22 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…capripneumoniae in goats (Balikci et al, ). In vitro excellent antimicrobial activity of fluoroquinolones against P. multocida isolates from cattle has been shown by Jamali and colleagues (). Treatment of pneumonia that requires antibiotic treatment for 3–5 days is a challenging task in food animals and repeated administration carries the risk of drug accumulation leading to drug residues in meat, milk or other animal‐derived food products.…”

Section: Introductionmentioning

confidence: 76%

Pharmacokinetic–pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats

Bhardwaj

Sidhu

Saini

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The pharmacokinetics (PK) and pharmacodynamics (PD) of marbofloxacin (MBF) were determined in six healthy female goats of age 1.00–1.25 years after repeated administration of MBF. The MBF was administered intramuscularly (IM) at 2 mg kg−1 day−1 for 5 days. Plasma concentrations of MBF were determined by high‐performance liquid chromatography, and PK parameters were obtained using noncompartmental analysis. The MBF concentrations peaked at 1 hr, and peak concentration (Cmax) was 1.760 µg/ml on day 1 and 1.817 µg/ml on day 5. Repeated dosing of MBF caused no significant change in PK parameters except area under curve (AUC) between day 1 (AUC0–∞D1 = 7.67 ± 0.719 µg × hr/ml) and day 5 (AUC0‐∞D5 = 8.70 ± 0.857 µg × hr/ml). A slight difference in mean residence time between 1st and 5th day of administration and accumulation index (AI = 1.13 ± 0.017) suggested lack of drug accumulation following repeated IM administration up to 5 days. Minimum inhibitory concentration (MIC) demonstrated that Escherichia coli (MIC = 0.04 µg/ml) and Pasturella multocida (MIC = 0.05 µg/ml) were highly sensitive to MBF. Time‐kill kinetics demonstrated rapid and concentration‐dependent activity of MBF against these pathogens. PK/PD integration of data for E. coli and P. multocida, using efficacy indices: Cmax/MIC and AUC0–24hr/MIC, suggested that IM administration of MBF at a dose of 2 mg kg−1 day−1 is appropriate to treat infections caused by E. coli. However, a dose of 5 mg kg−1 day−1 is recommended to treat pneumonia caused by P. multocida in goats. The study indicated that MBF can be used repeatedly at dosage of 2 mg/kg in goats without risk of drug accumulation up to 5 days.

show abstract

Section: Introductionmentioning

confidence: 76%

Pharmacokinetic–pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats

Bhardwaj

Sidhu

Saini

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…However, in the other studies [16,19,[30][31][32] it has been observed that virulence associated genes reported in P. multocida isolates were detected in different ratios. The variability observed in the presence of virulence associated genes might be due to the use of P. multocida isolates with different capsule types obtained from different hosts.…”

Section: Figure Band Profile Obtained Frommentioning

confidence: 90%

“…To date, many studies have been conducted to investigate the presence of virulence associated genes in P. multocida isolates [7][8][9]16,[30][31][32]. However, there are a limited number of studies evaluating the relationship between virulence genes and the health status of animals [7][8][9].…”

Section: Figure Band Profile Obtained Frommentioning

confidence: 99%

Investigation of biotype, genotype and virulence associated genes inPasteurella multocida capsular type A strains from the respiratory tract of cattle and their relationship with disease cases

Gülaydin¹,

Gürtürk²

2020

Turk J Vet Anim Sci

View full text Add to dashboard Cite

“…Portis et al (2012) reported a decrease in the numbers of P. multocida isolates (from clinically ill and necropsied animals) in US and Canadian diagnostic laboratories which were susceptible to tilmicosin between 2000 and 2009 and a three-fold increase in the MIC90 for tulathromycin over a 6 year period from 2004 to 2009. Resistance of P. multocida to the aminoglycosides and tetracyclines has been regularly reported (de Jong et al, 2014;Jamali et al, 2014). It is interesting to note that ceftiofur, a third generation cephalosporin that is resistant to the β-lactamases produced by P. multocida, has maintained its effectiveness since its introduction in 1988 (Watts and Sweeney, 2010).…”

Section: Pasteurella Multocidamentioning

confidence: 99%

Evolving views on bovine respiratory disease: An appraisal of selected key pathogens – Part 1

Murray

O’Neill²,

et al. 2016

The Veterinary Journal

View full text Add to dashboard Cite

Bovine respiratory disease (BRD) is one of the most commonly diagnosed causes of morbidity and mortality in cattle and interactions of factors associated with the animal, the pathogen and the environment are central to its pathogenesis. Emerging knowledge of a role for pathogens traditionally assumed to be minor players in the pathogenesis of BRD reflects an increasingly complex situation that will necessitate regular reappraisal of BRD pathogenesis and control. This review appraises the role of selected key pathogens implicated in BRD pathogenesis to assess how our understanding of their role has evolved in recent years.

show abstract

Prevalence, characterization and antibiotic resistance of Pasteurella multocida isolated from bovine respiratory infection

Cited by 25 publications

References 7 publications

Pharmacokinetic–pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats

Pharmacokinetic–pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats

Investigation of biotype, genotype and virulence associated genes inPasteurella multocida capsular type A strains from the respiratory tract of cattle and their relationship with disease cases

Evolving views on bovine respiratory disease: An appraisal of selected key pathogens – Part 1

Contact Info

Product

Resources

About